Advanced Filter

Filter by Group

Filter by Market Availability

Displaying all 2 drugs
Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.
Approved
Investigational
Matched Description: … Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind. Daratumumab was granted FDA approval on 16 November 2015. It is approved for...
Approved
Matched Synonyms: … Daratumumab
Matched Name: … Daratumumab
Matched Description: … Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. ... [A199002] Daratumumab was granted FDA approval on 16 November 2015. ... [L13290] It is approved for the treatment of multiple myeloma as monotherapy or combination therapy and
Matched Categories: … daratumumab ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Displaying all 2 drugs